64214-66-0Relevant articles and documents
Development of a tandem cyclization mediated by samarium(II) iodide: sequential intramolecular conjugate addition/nucleophilic acyl substitution
St. Jean Jr., David J.,Cheng, Edward P.,Bercot, Eric A.
, p. 6225 - 6227 (2006)
The development of a one-pot tandem intramolecular conjugate addition/nucleophilic acyl substitution using samarium(II) iodide is reported. The reaction relies on the reagent's unique ability to mediate both radical and anionic pathways, which are likely integral to the mechanism of this transformation. The tricyclic hemiacetal product was formed in good yield, with excellent diastereoselectivity, and its structure was verified by X-ray crystallographic analysis.
Pyrazolopyrimidine macrocyclic derivative and application thereof
-
Paragraph 0046, (2020/11/26)
The invention relates to a novel pyrazolopyrimidine macrocyclic derivative as well as a preparation method and application thereof in medicines. Specifically, the invention relates to a new pyrazolopyrimidine macrocyclic derivative as shown in a general formula (I), a preparation method thereof, and application of the pyrazolopyrimidine macrocyclic derivative or a pharmaceutical composition containing the derivative as a therapeutic agent, especially as a tropomyosin-related kinase (TRK) inhibitor, in treatment or prevention of TRK-mediated related diseases such as tumors. Substituents (R1, R2) and groups (X) in the general formula (I) are as defined in the description.
AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR
-
Paragraph 0061-0063, (2019/09/15)
Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.